162 related articles for article (PubMed ID: 11908246)
1. Survey of hospital policies regarding low-molecular-weight heparins.
Schumock GT; Nutescu EA; Walton SM; Arondekar BV; Lewis RK
Am J Health Syst Pharm; 2002 Mar; 59(6):534-8. PubMed ID: 11908246
[TBL] [Abstract][Full Text] [Related]
2. Survey of hospitals for guidelines, policies, and protocols for anticoagulants.
Vats V; Nutescu EA; Theobald JC; Wojtynek JE; Schumock GT
Am J Health Syst Pharm; 2007 Jun; 64(11):1203-8. PubMed ID: 17519463
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and cost savings of therapeutic interchange among U.S. hospitals.
Schachtner JM; Guharoy R; Medicis JJ; Newman N; Speizer R
Am J Health Syst Pharm; 2002 Mar; 59(6):529-33. PubMed ID: 11908245
[TBL] [Abstract][Full Text] [Related]
4. Selecting an agent for prophylaxis of venous thromboembolism.
Myers J
Am J Health Syst Pharm; 2006 Dec; 63(24):2448-50. PubMed ID: 17158692
[No Abstract] [Full Text] [Related]
5. Generic low-molecular-weight heparins: some practical considerations.
Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
[TBL] [Abstract][Full Text] [Related]
6. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
[TBL] [Abstract][Full Text] [Related]
7. Impact of removal and restriction of me-too medicines in a hospital drug formulary on in- and outpatient drug prescriptions: interrupted time series design with comparison group.
Vázquez-Mourelle R; Carracedo-Martínez E; Figueiras A
Implement Sci; 2019 Jul; 14(1):75. PubMed ID: 31340835
[TBL] [Abstract][Full Text] [Related]
8. Low-molecular-weight heparins in the treatment of deep-vein thrombosis.
Martineau P; Tawil N
Ann Pharmacother; 1998 May; 32(5):588-98, 601. PubMed ID: 9606481
[TBL] [Abstract][Full Text] [Related]
9. Hospital policies regarding herbal medicines.
Ansani NT; Ciliberto NC; Freedy T
Am J Health Syst Pharm; 2003 Feb; 60(4):367-70. PubMed ID: 12625219
[TBL] [Abstract][Full Text] [Related]
10. Overview on guidelines and recommendations for generic low-molecular-weight heparins.
Harenberg J
Thromb Res; 2011 Feb; 127 Suppl 3():S100-4. PubMed ID: 21262425
[TBL] [Abstract][Full Text] [Related]
11. The use of low molecular weight heparins for the prevention of postoperative venous thromboembolism in general surgery. A survey of practice in the United States.
Caprini JA; Arcelus J; Sehgal LR; Cohen EB; Reyna JJ
Int Angiol; 2002 Mar; 21(1):78-85. PubMed ID: 11941278
[TBL] [Abstract][Full Text] [Related]
12. ASHP national survey of pharmacy practice in hospital settings: prescribing and transcribing--2001.
Pedersen CA; Schneider PJ; Santell JP
Am J Health Syst Pharm; 2001 Dec; 58(23):2251-66. PubMed ID: 11763804
[TBL] [Abstract][Full Text] [Related]
13. Low molecular weight heparins copies: are they considered to be generics or biosimilars?
Minghetti P; Cilurzo F; Franzé S; Musazzi UM; Itri M
Drug Discov Today; 2013 Mar; 18(5-6):305-11. PubMed ID: 23153556
[TBL] [Abstract][Full Text] [Related]
14. ASHP national survey of pharmacy practice in hospital settings: prescribing and transcribing--2007.
Pedersen CA; Schneider PJ; Scheckelhoff DJ
Am J Health Syst Pharm; 2008 May; 65(9):827-43. PubMed ID: 18436730
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic equivalency of low-molecular-weight heparins.
McCart GM; Kayser SR
Ann Pharmacother; 2002 Jun; 36(6):1042-57. PubMed ID: 12022908
[TBL] [Abstract][Full Text] [Related]
16. ASHP national survey of hospital-based pharmaceutical services--1994.
Santell JP
Am J Health Syst Pharm; 1995 Jun; 52(11):1179-98. PubMed ID: 7656108
[TBL] [Abstract][Full Text] [Related]
17. Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients.
Cestac P; Bagheri H; Lapeyre-Mestre M; Sié P; Fouladi A; Maupas E; Léger P; Fontan B; Massip P; Montastruc JL
Drug Saf; 2003; 26(3):197-207. PubMed ID: 12580648
[TBL] [Abstract][Full Text] [Related]
18. Models of hospital drug policy in the UK.
Cotter SM; McKee M
J Health Serv Res Policy; 1997 Jul; 2(3):144-53. PubMed ID: 10180375
[TBL] [Abstract][Full Text] [Related]
19. Hospital policies for treatment of acute decompensated heart failure.
Vats V; DiDomenico RJ; Wojtynek JE; Theobald JC; Schumock GT
Ann Pharmacother; 2007 Apr; 41(4):562-7. PubMed ID: 17374618
[TBL] [Abstract][Full Text] [Related]
20. Hospital policies and practices on prevention and treatment of infections caused by methicillin-resistant Staphylococcus aureus.
Yang Y; McBride MV; Rodvold KA; Tverdek F; Trese AM; Hennenfent J; Schiff G; Lambert BL; Schumock GT
Am J Health Syst Pharm; 2010 Jun; 67(12):1017-24. PubMed ID: 20516473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
